Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance).
Andrew B NixonAlexander B SibleyYingmiao LiuAce J HatchChen JiangFlora MulkeyMark D StarrJohn C BradyDonna NiedzwieckiAlan P VenookLuis Baez-DiazHeinz-Josef LenzBert H O'NeilFederico InnocentiJeffrey A MeyerhardtEileen M O'ReillyKouros OwzarHerbert I HurwitzPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
In this exploratory, hypothesis-generating analysis, the Angiome identified multiple prognostic biomarkers and two potential predictive biomarkers for patients with mCRC enrolled in CALGB 80405. PlGF and VEGF-D predicted lack of benefit from bevacizumab in a chemo-dependent manner. See related commentaries by Mishkin and Kohn, p. 2722 and George and Bertagnolli, p. 2725.